A research institute specializing in Materials Science

Press release

R&D | KIMS established a research spin-off with antibacterial and antiviral additive technology

Page info

Date22-08-16 11:45 Hit338

Contents

KIMS established a research spin-off with antibacterial and antiviral additive technology

Preparing for the post-COVID-19 era with materials technology!


 

Korea Institute of Materials Science (KIMS), a government-funded research institute under the Ministry of Science and ICT, established a research spin-off, Twinwiz, based on functional antibacterial/antiviral additive technology. Twinwiz is located in Changwon Small Strong R&D Special Zone where KIMS is situated. A research spin-off is a company that has an Equity investment of more than 10 % from a government funded research institute for the direct commercialization of technology.



Twinwiz has succeeded in developing and commercializing an antibacterial and antiviral function material that does not change the appearance or physical properties of various products. The material is a liquid-type antibacterial and antiviral additive that generates high metal ions. Only a small amount of the additive to paints or various resins such as films and plastics can maximize antibacterial and antiviral functions of the existing products without changing optical, mechanical, and thermal properties.



Since this material can be added to the resin, it can be applied to existing products without any additional process and antibacterial and antiviral functions can be sustained semi-permanently. In addition, the material can easily remove harmful chemical compounds such as formaldehyde and ammonia, so it is effective in purifying indoor air, deodorizing, and solving sick building syndrome.



Dr. Chang-su Kim (CEO of Twinwiz), a principal researcher of the Department of Nano-bio Convergence at KIMS, said, "I feel proud of the application of the excellent technology for public purposes. Twinwiz will spare no effort to become a start-up that contributes to solving the problem of emerging infectious diseases in preparation for the post-COVID-19 era.”



Jung-hwan Lee, the President of KIMS, said, “We will continue to discover commercially great ideas and make efforts to materialize from the market point of view. KIMS will keep supporting and encouraging developing inroads into overseas markets.”

KIMS established a research spin-off with antibacterial and antiviral additive technology